programs by accessing the expertise or infrastructure of strategic collaborators or by developing drug candidates with potential applications outside of our strategic focus on cancer.Risks Associated with Our Business•We are a globally focused biopharmaceutical company and have a limited operating history, which may make it difficult to evaluate our
physicians, patients, third-party payors and others in the medical community necessary for commercial success.•If we are unable to obtain and maintain patent protection for our technology and drugs, our competitors could develop and
their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.•We have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing
staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting preclinical studies and clinical trials of our current drug candidates, such
revenue depends on a number of factors, including our ability to continue:•completing research regarding, and non-clinical and clinical development of, our drug candidates;•obtaining regulatory approvals and marketing authorizations for drug candidates for which we complete clinical trials;•obtaining adequate reimbursement from third-party payors, including government payors;•developing a sustainable and scalable manufacturing process for our drug candidates, including establishing and maintaining
will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our primary drug candidates: BGB-3111, BGB-A317,
potential that the FDA, CFDA, EMA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;•the number and characteristics of drug candidates that we may in-license and develop;•our ability to successfully commercialize our drug candidates;•the amount of sales and other revenues from drug candidates that we may commercialize, if any, including the selling prices for such
capabilities;•the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;•cash requirements of any future acquisitions and/or the development of other drug candidates;•the costs of operating as a public company;•the cost and timing of completion of commercial-scale outsourced manufacturing activities;•the time and cost necessary to respond to technological and market developments; and•the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.Until
including:•successful enrollment in, and completion of, preclinical studies and clinical trials;•receipt of regulatory approvals from the FDA, CFDA, EMA and other comparable regulatory authorities for our drug candidates, including
may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug
competitors to bring drugs to market before we do and impair our ability to commercialize our drug candidates and may harm our business and results of operations.Risks Related to Obtaining Regulatory Approval for Our Drug CandidatesThe regulatory approval processes of the FDA, CFDA, EMA and other comparable regulatory authorities
FDA, CFDA, EMA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent
may result from many factors, including:•our inability to obtain sufficient funds required for a clinical trial;•regulatory requests for additional analyses, reports, data, non-clinical and preclinical studies and clinical trials;•regulatory questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;•our inability to obtain approval from IRBs or ethics committees to conduct clinical trials at their respective sites;•manufacturing issues, including problems with manufacturing or timely obtaining from third parties sufficient quantities of a drug
addition, if we were able to obtain accelerated approval of any of our drug candidates, the FDA would require us to conduct a confirmatory study to verify the predicted clinical
Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize drug candidates in a timely
obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate in preclinical studies and well-controlled clinical
and distribution efforts may increase our expenses or divert our management's attention from the acquisition or development of drug candidates;•changes in a specific country's or region's political and cultural climate or economic condition;•differing regulatory requirements for drug approvals and marketing internationally;•difficulty of effective enforcement of contractual provisions in local jurisdictions;•potentially reduced protection for intellectual property rights;•potential third-party patent rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability, particularly in non-U.S. economies and markets;•compliance with tax, employment, immigration and labor laws for employees traveling abroad;•the effects of applicable non-U.S. tax structures and potentially adverse tax consequences;•currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to
of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates by the FDA, CFDA, EMA or other comparable regulatory